VA launches major clinical trial of psilocybin for PTSD and depression in veterans

Published Aug 6, 07:22 PM UTC

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Source reporting is collected, normalized, translated or condensed automatically when needed.
Page status: Automatically published source-backed update

How automation and AI are used · Report a correction or rights issue

The Department of Veterans Affairs is launching the PIVOT clinical trial to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The study will involve at least 240 veterans at five VA medical centers through June 2031, using a double-blind, randomized design with two doses of psilocybin or placebo alongside therapeutic support. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after psilocybin therapy. The initiative is backed by a Trump executive order accelerating psychedelic therapy research, and the VA is involved in 20 current clinical trials on psychedelic treatments including MDMA and LSD.

Source

Air Force TimesWestern

Original headline: Major VA study to examine effectiveness of psilocybin on depression, PTSD

Original language: EN

People and interests

Donald Trump Food and Drug Administration